HuniLife is committed to developing first-in-class therapeutics for unmet medical need, indicating the innovation-pursuing nature of HuniLife. The products in development at HuniLife are acquired from renowned research institutes or company through licensing or co-development. HuniLife plans to enable these products to be tested in clinic as soon as the required preclinical development works are completed.
There is one major platform technology for drug development at HuniLife, ENO1-targeting technology. HuL001 is a therapeutic antibody, based on the ENO1-targeting technology, and is designed for indications of autoimmune diseases and inflammatory disorder. HuL001 is expected to enter the Phase I by 2020.
HuniLife R&D pipeline